Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2007, Article ID 18797, 10 pages
http://dx.doi.org/10.1155/2007/18797
Review Article

The Role of Peroxisome Proliferator-Activated Receptors in Pulmonary Vascular Disease

Department of Medicine, Emory University, Atlanta Veterans Affairs Medical Center, Decatur, GA 30033, USA

Received 1 January 2007; Accepted 30 April 2007

Academic Editor: Jesse Roman

Copyright © 2007 Rachel E. Nisbet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar
  2. A. J. Gilde, K. A. J. M. van der Lee, P. H. M. Willemsen et al., “Peroxisome proliferator-activated receptor (PPAR) a and PPARß/d, but not PPAR?, modulate the expression of genes involved in cardiac lipid metabolism,” Circulation Research, vol. 92, no. 5, pp. 518–524, 2003. View at Publisher · View at Google Scholar
  3. I. Saluja, J. G. Granneman, and R. P. Skoff, “PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture,” GLIA, vol. 33, no. 3, pp. 191–204, 2001. View at Publisher · View at Google Scholar
  4. Y. Barak, D. Liao, W. He et al., “Effects of peroxisome proliferator-activated receptor d on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 303–308, 2002. View at Publisher · View at Google Scholar
  5. N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes,” Journal of Steroid Biochemistry and Molecular Biology, vol. 93, no. 2–5, pp. 99–105, 2005. View at Publisher · View at Google Scholar
  6. C.-H. Lee, A. Chawla, N. Urbiztondo et al., “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at Publisher · View at Google Scholar
  7. G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors a and ? induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar
  8. R. A. Daynes and D. C. Jones, “Emerging roles of PPARs in inflammation and immunity,” Nature Reviews Immunology, vol. 2, no. 10, pp. 748–759, 2002. View at Publisher · View at Google Scholar
  9. V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Standiford, “PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer,” Neoplasia, vol. 7, no. 3, pp. 294–301, 2005. View at Publisher · View at Google Scholar
  10. V. G. Keshamouni, R. C. Reddy, D. A. Arenberg et al., “Peroxisome proliferator-activated receptor-? activation inhibits tumor progression in non-small-cell lung cancer,” Oncogene, vol. 23, no. 1, pp. 100–108, 2004. View at Publisher · View at Google Scholar
  11. K. L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, and J.-A. Gustafsson, “Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1440–1444, 1993. View at Publisher · View at Google Scholar
  12. E. D. Rosen and B. M. Spiegelman, “PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth,” Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001. View at Publisher · View at Google Scholar
  13. H. E. Xu, T. B. Stanley, V. G. Montana et al., “Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARa,” Nature, vol. 415, no. 6873, pp. 813–817, 2002. View at Google Scholar
  14. F. Y. Ali, S. J. Davidson, L. A. Moraes et al., “Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARß,” The FASEB Journal, vol. 20, no. 2, pp. 326–328, 2006. View at Publisher · View at Google Scholar
  15. F. Y. Ali, K. Egan, G. A. FitzGerald et al., “Role of prostacyclin versus peroxisome proliferator-activated receptor ß receptors in prostacyclin sensing by lung fibroblasts,” American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 2, pp. 242–246, 2006. View at Publisher · View at Google Scholar
  16. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998. View at Publisher · View at Google Scholar
  17. H. S. Camp, O. Li, S. C. Wise et al., “Differential activation of peroxisome proliferator-activated receptor-? by troglitazone and rosiglitazone,” Diabetes, vol. 49, no. 4, pp. 539–547, 2000. View at Publisher · View at Google Scholar
  18. Y. Kodera, K.-I. Takeyama, A. Murayama, M. Suzawa, Y. Masuhiro, and S. Kato, “Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators,” Journal of Biological Chemistry, vol. 275, no. 43, pp. 33201–33204, 2000. View at Publisher · View at Google Scholar
  19. J. M. Olefsky, “Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists,” Journal of Clinical Investigation, vol. 106, no. 4, pp. 467–472, 2000. View at Google Scholar
  20. M. A. Haidara, H. Z. Yassin, M. Rateb, H. Ammar, and M. A. Zorkani, “Role of oxidative stress in development of cardiovascular complications in diabetes mellitus,” Current Vascular Pharmacology, vol. 4, no. 3, pp. 215–227, 2006. View at Publisher · View at Google Scholar
  21. R. E. Schmieder, “Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?” Journal of Hypertension, vol. 24, 2, pp. S31–S35, 2006. View at Publisher · View at Google Scholar
  22. R. Budhiraja, R. M. Tuder, and P. M. Hassoun, “Endothelial dysfunction in pulmonary hypertension,” Circulation, vol. 109, no. 2, pp. 159–165, 2004. View at Publisher · View at Google Scholar
  23. A. Hyduk, J. B. Croft, C. Ayala, K. Zheng, Z. J. Zheng, and G. A. Mensah, “Pulmonary hypertension surveillance—United States, 1980–2002,” Morbidity and Mortality Weekly Report, vol. 54, no. 5, pp. 1–28, 2005. View at Google Scholar
  24. L. Du, C. C. Sullivan, D. Chu et al., “Signaling molecules in nonfamilial pulmonary hypertension,” The New England Journal of Medicine, vol. 348, no. 6, pp. 500–509, 2003. View at Publisher · View at Google Scholar
  25. J. H. Newman, L. Wheeler, K. B. Lane et al., “Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred,” The New England Journal of Medicine, vol. 345, no. 5, pp. 319–324, 2001. View at Publisher · View at Google Scholar
  26. U. C. Garg and A. Hassid, “Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells,” Journal of Clinical Investigation, vol. 83, no. 5, pp. 1774–1777, 1989. View at Google Scholar
  27. H. Azuma, M. Ishikawa, and S. Sekizaki, “Endothelium-dependent inhibition of platelet aggregation,” British Journal of Pharmacology, vol. 88, no. 2, pp. 411–415, 1986. View at Google Scholar
  28. A. P. L. Smith, E. A. G. Demoncheaux, and T. W. Higenbottam, “Nitric oxide gas decreases endothelin-1 mRNA in cultured pulmonary artery endothelial cells,” Nitric Oxide, vol. 6, no. 2, pp. 153–159, 2002. View at Publisher · View at Google Scholar
  29. M. A. Perrella, E. S. Edell, M. J. Krowka, D. A. Cortese, and J. C. Burnett Jr., “Endothelium-derived relaxing factor in pulmonary and renal circulations during hypoxia,” American Journal of Physiology, vol. 263, no. 1, part 2, pp. R45–R50, 1992. View at Google Scholar
  30. F. Ichinose, R. Ullrich, A. Sapirstein et al., “Cytosolic phospholipase A2 in hypoxic pulmonary vasoconstriction,” Journal of Clinical Investigation, vol. 109, no. 11, pp. 1493–1500, 2002. View at Publisher · View at Google Scholar
  31. J. Wang, M. Juhaszova, L. J. Rubin, and X.-J. Yuan, “Hypoxia inhibits gene expression of voltage-gated K+ channel α subunits in pulmonary artery smooth muscle cells,” Journal of Clinical Investigation, vol. 100, no. 9, pp. 2347–2353, 1997. View at Google Scholar
  32. S. Adnot, B. Raffestin, S. Eddahibi, P. Braquet, and P.-E. Chabrier, “Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia,” Journal of Clinical Investigation, vol. 87, no. 1, pp. 155–162, 1991. View at Google Scholar
  33. R. H. Steinhorn, J. A. Russell, S. Lakshminrusimha, S. F. Gugino, S. M. Black, and J. R. Fineman, “Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension,” American Journal of Physiology, vol. 280, no. 1, pp. H311–H317, 2001. View at Google Scholar
  34. R. M. Tuder, C. D. Cool, M. W. Geraci et al., “Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 6, pp. 1925–1932, 1999. View at Google Scholar
  35. L. P. McQuillan, G. K. Leung, P. A. Marsden, S. K. Kostyk, and S. Kourembanas, “Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms,” American Journal of Physiology, vol. 267, no. 5, part 2, pp. H1921–H1927, 1994. View at Google Scholar
  36. A. Giaid and D. Saleh, “Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension,” The New England Journal of Medicine, vol. 333, no. 4, pp. 214–221, 1995. View at Publisher · View at Google Scholar
  37. C. Xue and R. A. Johns, “Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension,” The New England Journal of Medicine, vol. 333, no. 24, pp. 1642–1644, 1995. View at Publisher · View at Google Scholar
  38. J. P. Khoo, L. Zhao, N. J. Alp et al., “Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension,” Circulation, vol. 111, no. 16, pp. 2126–2133, 2005. View at Publisher · View at Google Scholar
  39. M. Nandi, A. Miller, R. Stidwill et al., “Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse,” Circulation, vol. 111, no. 16, pp. 2086–2090, 2005. View at Publisher · View at Google Scholar
  40. P. Rosenkranz-Weiss, W. C. Sessa, S. Milstien, S. Kaufman, C. A. Watson, and J. S. Pober, “Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity,” Journal of Clinical Investigation, vol. 93, no. 5, pp. 2236–2243, 1994. View at Google Scholar
  41. S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, and A. M. Zeiher, “Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation,” Nature, vol. 399, no. 6736, pp. 601–605, 1999. View at Publisher · View at Google Scholar
  42. D. Fulton, J.-P. Gratton, T. J. McCabe et al., “Regulation of endothelium-derived nitric oxide production by the protein kinase Akt,” Nature, vol. 399, no. 6736, pp. 597–601, 1999. View at Publisher · View at Google Scholar
  43. T. Murata, M. Hori, K. Sakamoto, H. Karaki, and H. Ozaki, “Dexamethasone blocks hypoxia-induced endothelial dysfunction in organ-cultured pulmonary arteries,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 6, pp. 647–655, 2004. View at Publisher · View at Google Scholar
  44. G. G. Konduri, J. Ou, Y. Shi, and K. A. Pritchard Jr., “Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension,” American Journal of Physiology, vol. 285, no. 1, pp. H204–H211, 2003. View at Google Scholar
  45. G. García-Cardeña, R. Fan, V. Shah et al., “Dynamic activation of endothelial nitric oxide synthase by Hsp90,” Nature, vol. 392, no. 6678, pp. 821–824, 1998. View at Publisher · View at Google Scholar
  46. T. Murata, K. Sato, M. Hori, H. Ozaki, and H. Karaki, “Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension,” Journal of Biological Chemistry, vol. 277, no. 46, pp. 44085–44092, 2002. View at Publisher · View at Google Scholar
  47. S. Muzaffar, N. Shukla, G. D. Angelini, and J. Y. Jeremy, “Acute hypoxia simultaneously induces the expression of gp91phox and endothelial nitric oxide synthase in the porcine pulmonary artery,” Thorax, vol. 60, no. 4, pp. 305–313, 2005. View at Publisher · View at Google Scholar
  48. K. A. Pritchard Jr., A. W. Ackerman, E. R. Gross et al., “Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase,” Journal of Biological Chemistry, vol. 276, no. 21, pp. 17621–17624, 2001. View at Publisher · View at Google Scholar
  49. J. S. Beckman and W. H. Koppenol, “Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly,” American Journal of Physiology, vol. 271, no. 5, part 1, pp. C1424–C1437, 1996. View at Google Scholar
  50. N. Kuzkaya, N. Weissmann, D. G. Harrison, and S. Dikalov, “Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase,” Journal of Biological Chemistry, vol. 278, no. 25, pp. 22546–22554, 2003. View at Publisher · View at Google Scholar
  51. U. Landmesser, S. Dikalov, S. R. Price et al., “Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension,” Journal of Clinical Investigation, vol. 111, no. 8, pp. 1201–1209, 2003. View at Publisher · View at Google Scholar
  52. S. Mehta, D. J. Stewart, D. Langleben, and R. D. Levy, “Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension,” Circulation, vol. 92, no. 6, pp. 1539–1545, 1995. View at Google Scholar
  53. R. N. Channick, J. W. Newhart, F. W. Johnson et al., “Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests,” Chest, vol. 109, no. 6, pp. 1545–1549, 1996. View at Google Scholar
  54. C. Marshall, A. J. Mamary, A. J. Verhoeven, and B. E. Marshall, “Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction,” American Journal of Respiratory Cell and Molecular Biology, vol. 15, no. 5, pp. 633–644, 1996. View at Google Scholar
  55. N. Weissmann, S. Zeller, R. U. Schäfer et al., “Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction,” American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 4, pp. 505–513, 2006. View at Publisher · View at Google Scholar
  56. J. Q. Liu, I. N. Zelko, E. M. Erbynn, J. S. K. Sham, and R. J. Folz, “Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox),” American Journal of Physiology, vol. 290, no. 1, pp. L2–L10, 2006. View at Publisher · View at Google Scholar
  57. J. Q. Liu, E. M. Erbynn, and R. J. Folz, “Chronic hypoxia-enhanced murine pulmonary vasoconstriction: role of superoxide and gp91phox,” Chest, vol. 128, no. 6 supplement, pp. 594S–596S, 2005. View at Publisher · View at Google Scholar
  58. J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart, “Peroxisome proliferator-activated receptor γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ-dependent mechanisms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1810–1816, 2005. View at Publisher · View at Google Scholar
  59. D. S. Calnek, L. J. Mazzella, S. Roser, J. Roman, and C. M. Hart, “Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 52–57, 2003. View at Publisher · View at Google Scholar
  60. I. Inoue, S.-I. Goto, T. Matsunaga et al., “The ligands/activators for peroxisome proliferator-activated receptor a (PPARa) and PPAR? increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells,” Metabolism, vol. 50, no. 1, pp. 3–11, 2001. View at Publisher · View at Google Scholar
  61. J. Hwang, D. J. Kleinhenz, B. Lasségue, K. K. Griendling, S. Dikalov, and C. M. Hart, “Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production,” American Journal of Physiology, vol. 288, no. 4, pp. C899–C905, 2005. View at Publisher · View at Google Scholar
  62. M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin, “Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 45–51, 2003. View at Publisher · View at Google Scholar
  63. K. Kato, H. Satoh, Y. Endo et al., “Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPAR? in endothelial function,” Biochemical and Biophysical Research Communications, vol. 258, no. 2, pp. 431–435, 1999. View at Publisher · View at Google Scholar
  64. R. E. Law, W. P. Meehan, X.-P. Xi et al., “Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia,” Journal of Clinical Investigation, vol. 98, no. 8, pp. 1897–1905, 1996. View at Google Scholar
  65. X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo,” Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999. View at Publisher · View at Google Scholar
  66. F. J. Schopfer, Y. Lin, P. R. S. Baker et al., “Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor ? ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340–2345, 2005. View at Publisher · View at Google Scholar
  67. T. Cui, F. J. Schopfer, J. Zhang et al., “Nitrated fatty acids: endogenous anti-inflammatory signaling mediators,” Journal of Biological Chemistry, vol. 281, no. 47, pp. 35686–35698, 2006. View at Publisher · View at Google Scholar
  68. U. Ikeda, M. Shimpo, Y. Murakami, and K. Shimada, “Peroxisome proliferator-activated receptor-γ ligands inhibit nitric oxide synthesis in vascular smooth muscle cells,” Hypertension, vol. 35, no. 6, pp. 1232–1236, 2000. View at Google Scholar
  69. K. Murao, H. Imachi, A. Momoi et al., “Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells,” FEBS Letters, vol. 454, no. 1-2, pp. 27–30, 1999. View at Publisher · View at Google Scholar
  70. S. M. Jackson, F. Parhami, X.-P. Xi et al., “Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 9, pp. 2094–2104, 1999. View at Google Scholar
  71. H. F. Frasch, C. Marshall, and B. E. Marshall, “Endothelin-1 is elevated in monocrotaline pulmonary hypertension,” American Journal of Physiology, vol. 276, no. 2, part 1, pp. L304–L310, 1999. View at Google Scholar
  72. H. Li, S.-J. Chen, Y.-F. Chen et al., “Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia,” Journal of Applied Physiology, vol. 77, no. 3, pp. 1451–1459, 1994. View at Google Scholar
  73. N. L. Jernigan, B. R. Walker, and T. C. Resta, “Endothelium-derived reactive oxygen species and endothelin-1 attenuate NO-dependent pulmonary vasodilation following chronic hypoxia,” American Journal of Physiology, vol. 287, no. 4, pp. L801–L808, 2004. View at Publisher · View at Google Scholar
  74. P. Delerive, F. Martin-Nizard, G. Chinetti et al., “Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway,” Circulation Research, vol. 85, no. 5, pp. 394–402, 1999. View at Google Scholar
  75. F. Martin-Nizard, C. Furman, P. Delerive et al., “Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells,” Journal of Cardiovascular Pharmacology, vol. 40, no. 6, pp. 822–831, 2002. View at Publisher · View at Google Scholar
  76. H. Olschewski, F. Rose, R. Schermuly et al., “Prostacyclin and its analogues in the treatment of pulmonary hypertension,” Pharmacology and Therapeutics, vol. 102, no. 2, pp. 139–153, 2004. View at Publisher · View at Google Scholar
  77. M. W. Geraci, B. Gao, D. C. Shepherd et al., “Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension,” Journal of Clinical Investigation, vol. 103, no. 11, pp. 1509–1515, 1999. View at Google Scholar
  78. Y. Hoshikawa, N. F. Voelkel, T. L. Gesell et al., “Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 2, pp. 314–318, 2001. View at Google Scholar
  79. I. M. Robbins, J. D. Morrow, and B. W. Christman, “Oxidant stress but not thromboxane decreases with epoprostenol therapy,” Free Radical Biology and Medicine, vol. 38, no. 5, pp. 568–574, 2005. View at Publisher · View at Google Scholar
  80. E. B. Rosenzweig and R. J. Barst, “Pulmonary arterial hypertension: a comprehensive review of pharmacological treatment,” Treatments in Respiratory Medicine, vol. 5, no. 2, pp. 117–127, 2006. View at Publisher · View at Google Scholar
  81. D. Bishop-Bailey, “Peroxisome proliferator-activated receptors in the cardiovascular system,” British Journal of Pharmacology, vol. 129, no. 5, pp. 823–834, 2000. View at Publisher · View at Google Scholar
  82. M. E. Burleigh, V. R. Babaev, J. A. Oates et al., “Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice,” Circulation, vol. 105, no. 15, pp. 1816–1823, 2002. View at Publisher · View at Google Scholar
  83. R. E. Law, S. Goetze, X.-P. Xi et al., “Expression and function of PPAR? in rat and human vascular smooth muscle cells,” Circulation, vol. 101, no. 11, pp. 1311–1318, 2000. View at Google Scholar
  84. K. Subbaramaiah, D. T. Lin, J. C. Hart, and A. J. Dannenberg, “Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300,” Journal of Biological Chemistry, vol. 276, no. 15, pp. 12440–12448, 2001. View at Publisher · View at Google Scholar
  85. J.-Y. Liou, S. Lee, D. Ghelani, N. Matijevic-Aleksic, and K. K. Wu, “Protection of endothelial survival by peroxisome proliferator-activated receptor-δ mediated 14-3-3 upregulation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1481–1487, 2006. View at Publisher · View at Google Scholar
  86. Z. Wang, N. Jin, S. Ganguli, D. R. Swartz, L. Li, and R. A. Rhoades, “Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction,” American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 5, pp. 628–635, 2001. View at Google Scholar
  87. T. Nagaoka, Y. Morio, N. Casanova et al., “Rho/Rho-kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats,” American Journal of Physiology, vol. 287, no. 4, pp. L665–L672, 2004. View at Publisher · View at Google Scholar
  88. T. P. Robertson, M. Dipp, J. P. T. Ward, P. I. Aaronson, and A. M. Evans, “Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat,” British Journal of Pharmacology, vol. 131, no. 1, pp. 5–9, 2000. View at Publisher · View at Google Scholar
  89. K. A. Fagan, M. Oka, N. R. Bauer et al., “Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase,” American Journal of Physiology, vol. 287, no. 4, pp. L656–L664, 2004. View at Publisher · View at Google Scholar
  90. K. Abe, H. Shimokawa, K. Morikawa et al., “Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats,” Circulation Research, vol. 94, no. 3, pp. 385–393, 2004. View at Publisher · View at Google Scholar
  91. T. Nagaoka, K. A. Fagan, S. A. Gebb et al., “Inhaled Rho-kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 5, pp. 494–499, 2005. View at Publisher · View at Google Scholar
  92. J.-M. Hyvelin, K. Howell, A. Nichol, C. M. Costello, R. J. Preston, and P. McLoughlin, “Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation,” Circulation Research, vol. 97, no. 2, pp. 185–191, 2005. View at Publisher · View at Google Scholar
  93. S. Wakino, K. Hayashi, T. Kanda et al., “Peroxisome proliferator-activated receptor ? ligands inhibit Rho/Rho-kinase pathway by inducing protein tyrosine phosphatase SHP-2,” Circulation Research, vol. 95, no. 5, pp. e45–e55, 2004. View at Publisher · View at Google Scholar
  94. Y. Chang, B. Ceacareanu, M. Dixit, N. Sreejayan, and A. Hassid, “Nitric oxide-induced motility in aortic smooth muscle cells: role of protein tyrosine phosphatase SHP-2 and GTP-binding protein Rho,” Circulation Research, vol. 91, no. 5, pp. 390–397, 2002. View at Publisher · View at Google Scholar
  95. Z. Chen, S. Ishibashi, S. Perrey et al., “Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 372–377, 2001. View at Google Scholar
  96. A. R. Collins, W. P. Meehan, U. Kintscher et al., “Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 365–371, 2001. View at Google Scholar
  97. A. C. Li, K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass, “Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice,” Journal of Clinical Investigation, vol. 106, no. 4, pp. 523–531, 2000. View at Google Scholar
  98. S. Goetze, A. Bungenstock, C. Czupalla et al., “Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR?-ligands,” Hypertension, vol. 40, no. 5, pp. 748–754, 2002. View at Publisher · View at Google Scholar
  99. C. M. Halabi and C. D. Sigmund, “Peroxisome proliferator-activated receptor-γ and its agonists in hypertension and atherosclerosis: mechanisms and clinical implications,” American Journal of Cardiovascular Drugs, vol. 5, no. 6, pp. 389–398, 2005. View at Publisher · View at Google Scholar
  100. R. Avena, M. E. Mitchell, E. S. Nylen, K. M. Curry, and A. N. Sidawy, “Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes,” Journal of Vascular Surgery, vol. 28, no. 6, pp. 1024–1032, 1998, discussion 1031–1032. View at Publisher · View at Google Scholar
  101. L. Cominacini, U. Garbin, A. Fratta Pasini et al., “Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients,” Diabetes, vol. 47, no. 1, pp. 130–133, 1998. View at Publisher · View at Google Scholar
  102. T. Murakami, S. Mizuno, K. Ohsato et al., “Effects of troglitazone on frequency of coronary vasospastic-lnduced angina pectoris in patients with diabetes mellitus,” American Journal of Cardiology, vol. 84, no. 1, pp. 92–94, 1999. View at Publisher · View at Google Scholar
  103. A. B. Walker, P. D. Chattington, R. E. Buckingham, and G. Williams, “The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats,” Diabetes, vol. 48, no. 7, pp. 1448–1453, 1999. View at Publisher · View at Google Scholar
  104. Q. N. Diep, M. El Mabrouk, J. S. Cohn et al., “Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-?,” Circulation, vol. 105, no. 19, pp. 2296–2302, 2002. View at Publisher · View at Google Scholar
  105. K. Takeda, T. Ichiki, T. Tokunou et al., “Peroxisome proliferator-activated receptor ? activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells,” Circulation, vol. 102, no. 15, pp. 1834–1839, 2000. View at Google Scholar
  106. J. Minamikawa, S. Tanaka, M. Yamauchi, D. Inoue, and H. Koshiyama, “Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 5, pp. 1818–1820, 1998. View at Publisher · View at Google Scholar
  107. T. Takagi, T. Akasaka, A. Yamamuro et al., “Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study,” Journal of the American College of Cardiology, vol. 36, no. 5, pp. 1529–1535, 2000. View at Publisher · View at Google Scholar
  108. J. S. Sidhu, Z. Kaposzta, H. S. Markus, and J. C. Kaski, “Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 930–934, 2004. View at Publisher · View at Google Scholar
  109. J. Hetzel, B. Balletshofer, K. Rittig et al., “Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1804–1809, 2005. View at Publisher · View at Google Scholar
  110. U. Campia, L. A. Matuskey, and J. A. Panza, “Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors,” Circulation, vol. 113, no. 6, pp. 867–875, 2006. View at Publisher · View at Google Scholar
  111. S. Ameshima, H. Golpon, C. D. Cool et al., “Peroxisome proliferator-activated receptor gamma (PPAR?) expression is decreased in pulmonary hypertension and affects endothelial cell growth,” Circulation Research, vol. 92, no. 10, pp. 1162–1169, 2003. View at Publisher · View at Google Scholar
  112. D. Bishop-Bailey and T. Hla, “Endothelial cell apoptosis induced by the peroxisome proliferator- activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2,” Journal of Biological Chemistry, vol. 274, no. 24, pp. 17042–17048, 1999. View at Publisher · View at Google Scholar
  113. M. B. Dancu, D. E. Berardi, J. P. Vanden Heuvel, and J. M. Tarbell, “Asynchronous shear stress and circumferential strain reduces endothelial NO synthase and cyclooxygenase-2 but induces endothelin-1 gene expression in endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 2088–2094, 2004. View at Publisher · View at Google Scholar
  114. J. Hwang, A. Saha, Y. C. Boo et al., “Oscillatory shear stress stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion,” Journal of Biological Chemistry, vol. 278, no. 47, pp. 47291–47298, 2003. View at Publisher · View at Google Scholar
  115. J. S. McNally, M. E. Davis, D. P. Giddens et al., “Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress,” American Journal of Physiology, vol. 285, no. 6, pp. H2290–H2297, 2003. View at Google Scholar
  116. Y. Matsuda, Y. Hoshikawa, S. Ameshima et al., “Effects of peroxisome proliferator-activated receptor ? ligands on monocrotaline-induced pulmonary hypertension in rats,” Nihon Kokyuki Gakkai Zasshi, vol. 43, no. 5, pp. 283–288, 2005. View at Google Scholar
  117. Y. Lin, X. Zhu, F. L. McIntee et al., “Interferon regulatory factor-1 mediates PPARγ-induced apoptosis in vascular smooth muscle cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 2, pp. 257–263, 2004. View at Publisher · View at Google Scholar
  118. T. Okura, M. Nakamura, Y. Takata, S. Watanabe, Y. Kitami, and K. Hiwada, “Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells,” European Journal of Pharmacology, vol. 407, no. 3, pp. 227–235, 2000. View at Publisher · View at Google Scholar
  119. K. R. Stenmark and I. F. McMurtry, “Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal?” Circulation Research, vol. 97, no. 2, pp. 95–98, 2005. View at Publisher · View at Google Scholar
  120. J. T. Crossno Jr., K. G. Morris Jr., and D. J. Klemm, “Attenuation of hypoxia-induced pulmonary artery remodeling by a peroxisome proliferator-activated receptor-γ agonist,” Chest, vol. 128, 6, p. 580S, 2005. View at Publisher · View at Google Scholar
  121. J. Hwang, D. J. Kleinhenz, H. L. Rupnow et al., “The PPAR? ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice,” Vascular Pharmacology, vol. 46, no. 6, pp. 456–462, 2007. View at Publisher · View at Google Scholar